Incyte (INCY) Net Cash Flow (2010 - 2026)
Incyte's (INCY) quarterly Net Cash Flow came in at $521.3 million in Q2 2026, up 3465.1% YoY from $14.6 million in Q2 2025, and up 42.45% on a QoQ basis from $366.0 million in Q1 2026.
Incyte (INCY) Net Cash Flow (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Net Cash Flow data on file, last reported at $521.3 million in Q2 2026.
- Quarterly Net Cash Flow rose 3465.1% year-over-year to $521.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.0 billion (up 110.15% YoY) and the FY2025 annual result came in at $1.4 billion, up 192.36% from the prior year.
- Net Cash Flow grew to $521.3 million in Q2 2026, from $366.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $643.6 million in Q4 2025 to a low of -$2.4 billion in Q2 2024.
- A 5-year average of $107.2 million and a median of $254.1 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 6016.68% in 2024, down 856.15% in 2024.
- Tracing INCY's Net Cash Flow over 5 years: stood at $260.3 million in 2022, then plunged by 102.47% to -$6.4 million in 2023, then surged by 6016.68% to $380.1 million in 2024, then surged by 69.31% to $643.6 million in 2025, then declined by 19.0% to $521.3 million in 2026.
- The last three Net Cash Flow figures came in at $521.3 million (Q2 2026), $366.0 million (Q1 2026), and $643.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 521.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 521.33 Mn |
| Jun 30, 2026 | 521.33 Mn |
| Mar 31, 2026 | 365.97 Mn |
| Mar 31, 2026 | 365.97 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Jun 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | -2.36 Bn |
| Mar 31, 2024 | 133.29 Mn |
| Mar 31, 2024 | 133.29 Mn |